Successful treatment of a patient with primary Sjögren's syndrome with Rituximab

Clinical Rheumatology

Volumn 25, Issue 6, 2006, Pages 891-894

  Ring, Troels ^a   Kallenbach, Maria ^a   Prætorius, Jeppe ^b   Nielsen, Søren ^b   Melgaard, Birgitte ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Aquaporins; B cell depletion; Primary Sj gren's syndrome; Rituximab

Indexed keywords

ANTINUCLEAR ANTIBODY; AQUAPORIN 1; AQUAPORIN 5; BICARBONATE; CD20 ANTIGEN; CITRATE POTASSIUM; IMMUNOGLOBULIN G; RITUXIMAB; SODIUM POTASSIUM CHLORIDE COTRANSPORTER;

ABSENCE OF SIDE EFFECTS; ACINAR CELL; ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; DYSPNEA; ECHOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOSALIVATION; KIDNEY CALCIFICATION; KIDNEY TUBULE ACIDOSIS; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; METABOLIC ACIDOSIS; MYOEPITHELIUM CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY ALKALOSIS; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA;

ACIDOSIS, RENAL TUBULAR; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AQUAPORIN 1; AQUAPORIN 5; B-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOCYTES; MIDDLE AGED; SALIVARY GLANDS; SJOGREN'S SYNDROME; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 33749164988     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-005-0086-0     Document Type: Article

References (15)

1. Groom J, Kalled SL, Cutler AH et al (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109:59-68
2. Somer BG, Tsai DE, Downs L, Weinstein B, Shuster SJ (2003) Improvement in Sjögren's syndrome following therapy with Rituximab for marginal zone lymphoma. Arthritis Rheum 49:394-398
3. Cragg MS, Walshe CA, Ivanóv AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140-174
4. Venables PJW (2004) Sjögren's syndrome. Best Pract Res Clin Rheumatol 18:313-329
5. Cavill D, Waterman SA, Gordon TP (2004) Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjögren's syndrome. Scand J Immunol 59:261-266
6. Maruyama T, Saito I, Hayashi Y, Kompfner E, Fox RI, Burton DR, Ditzel HJ (2004) Molecular analysis of the human autoantibody response to α-fodrin in Sjögren's syndrome reveals novel apoptosis-induced specificity. Am J Pathol 165:53-61
7. Turner RJ, Sugiya H (2002) Understanding salivary fluid and protein secretion. Oral Dis 8:3-11
8. Matsuzaki T, Tajika Y, Ablimit A, Aoki T, Hagiwara H, Takata K (2004) Aquaporins in the digestive system. Med Electron Microsc 37:71-80
9. Beroukas D, Hiscock J, Gannon BJ, Jonsson R, Gordon TP, Waterman SA (2002) Selective down-regulation of aquaporin-1 in salivary glands in primary Sjögren's syndrome. Lab Invest 82:1547-1552
10. Li J, Ha YM, Kü NY, Choi SY, Lee SJ, Oh SB, Kim JS, Lee JH, Lee EB, Song YW, Park K (2004) Inhibitory effects of autoantibodies on muscarinic receptors in Sjögren's syndrome. Lab Invest 84:1430-1438
11. Gresz V, Kwon T-H, Gong H, Agre P, Steward MC, King LS, Nielsen S (2004) Immunolocalization of AQP-5 in rat parotid and submandibular salivary glands after stimulation or inhibition of secretion in vivo. Am J Physiol 287:G151-G161
12. Ishikawa Y, Inoue N, Zhenfang Y, Nakae Y (2004) Molecular mechanisms and drug development in aquaporin water channel diseases: The translocation of aquaporin-5 from lipid rafts to the apical plasma membrane of parotid glands of normal rats and the impairment of it in diabetic or aged rats. J Pharmacol Sci 96:271-275
13. Kallenbach M, Duan H, Ring T (2005) Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 99:c92-c96
14. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J (2004) Inefficacy of infliximab in primary Sjögren's syndrome. Arthritis Rheum 50:1270-1276
15. Pijpe J, Van Imhoff GW, Vissink A, Van der Wal JE, Kluin PM, Spijkervet FKL, Kallenberg CGM, Bootsma H (2004) Changes in salivary gland immunohistology and function after rituximab mono-therapy in a patient with Sjögren's syndrome and associated MALT-lymphoma. Ann Rheum Dis (epub ahead of print) http://Doi:10.1136/ard.2004.030684